Publicaciones (44) Publicaciones en las que ha participado algún/a investigador/a

2013

  1. A predictive pharmacokinetic/pharmacodynamic model of fentanyl for analgesia/sedation in neonates based on a semi-physiologic approach

    Pediatric Drugs, Vol. 15, Núm. 3, pp. 247-257

  2. A role for hypocretin/orexin receptor-1 in cue-induced reinstatement of nicotine-seeking behavior

    Neuropsychopharmacology, Vol. 38, Núm. 9, pp. 1724-1736

  3. Additive effect of rimonabant and citalopram on extracellular serotonin levels monitored with in vivo microdialysis in rat brain

    European Journal of Pharmacology, Vol. 709, Núm. 1-3, pp. 13-19

  4. An investigation of interactions between hypocretin/orexin signaling and glutamate receptor surface expression in the rat nucleus accumbens under basal conditions and after cocaine exposure

    Neuroscience Letters, Vol. 557, Núm. PB, pp. 101-106

  5. Analysis of Sp transcription factors in the postmortem brain of chronic schizophrenia: A pilot study of relationship to negative symptoms

    Journal of Psychiatric Research, Vol. 47, Núm. 7, pp. 926-934

  6. Antidepressant-like properties of three new α2-adrenoceptor antagonists

    Neuropharmacology, Vol. 65, pp. 13-19

  7. Antipsychotics and seizures: Higher risk with atypicals?

    Seizure, Vol. 22, Núm. 2, pp. 141-143

  8. Behavioral, neurochemical and morphological changes induced by the overexpression of munc18-1a in brain of mice: relevance to schizophrenia.

    Translational psychiatry, Vol. 3

  9. Brain RGS4 and RGS10 protein expression in schizophrenia and depression. Effect of drug treatment

    Psychopharmacology, Vol. 226, Núm. 1, pp. 177-188

  10. Calcium as main trigger of mitochondrial oxidant stress in Parkinson's disease

    Movement Disorders

  11. Chronic effects of cannabinoid drugs on monoaminergic systems and the role of endocannabinoids and cannabinoid receptors in human brain disorders

    Endocannabinoid Regulation of Monoamines in Psychiatric and Neurological Disorders (Springer New York), pp. 213-238

  12. Chronic effects of corticosterone on GIRK1-3 subunits and 5-HT1A receptor expression in rat brain and their reversal by concurrent fluoxetine treatment

    European Neuropsychopharmacology, Vol. 23, Núm. 3, pp. 229-239

  13. Chronic pain leads to concomitant noradrenergic impairment and mood disorders

    Biological Psychiatry, Vol. 73, Núm. 1, pp. 54-62

  14. Cooperativity between calmodulin-binding sites in Kv7.2 channels

    Journal of Cell Science, Vol. 126, Núm. 1, pp. 244-253

  15. Cyclin-dependent kinase-5 and p35/p25 activators in schizophrenia and major depression prefrontal cortex: Basal contents and effects of psychotropic medications

    International Journal of Neuropsychopharmacology, Vol. 16, Núm. 3, pp. 683-689

  16. Description of a bivalent cannabinoid ligand with hypophagic properties

    Archiv der Pharmazie, Vol. 346, Núm. 3, pp. 171-179

  17. Determination of total plasma hydroperoxides using a diphenyl-1- pyrenylphosphine fluorescent probe

    Analytical Biochemistry, Vol. 434, Núm. 1, pp. 172-177

  18. Domperidone in Parkinson's disease: a perilous arrhythmogenic or the gold standard?

    Current drug safety, Vol. 8, Núm. 1, pp. 63-68

  19. Dopamine-dependent long-term depression at subthalamo-nigral synapses is lost in experimental parkinsonism

    Journal of Neuroscience, Vol. 33, Núm. 36, pp. 14331-14341

  20. Dysregulated 5-HT2A receptor binding in postmortem frontal cortex of schizophrenic subjects

    European Neuropsychopharmacology, Vol. 23, Núm. 8, pp. 852-864